Bernard Wealth Management Corp. Takes $36,000 Position in Astera Labs, Inc. $ALAB

Bernard Wealth Management Corp. acquired a new stake in Astera Labs, Inc. (NASDAQ:ALAB) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 400 shares of the company’s stock, valued at approximately $36,000.

Several other hedge funds have also modified their holdings of ALAB. Fred Alger Management LLC lifted its holdings in Astera Labs by 13.0% during the 1st quarter. Fred Alger Management LLC now owns 1,560,033 shares of the company’s stock worth $93,087,000 after buying an additional 179,638 shares during the last quarter. Hoey Investments Inc. lifted its holdings in Astera Labs by 22.4% during the 2nd quarter. Hoey Investments Inc. now owns 6,121 shares of the company’s stock worth $553,000 after buying an additional 1,121 shares during the last quarter. Wealth Effects LLC purchased a new stake in Astera Labs during the 2nd quarter worth about $242,000. Realta Investment Advisors purchased a new stake in Astera Labs during the 2nd quarter worth about $214,000. Finally, Sheets Smith Wealth Management purchased a new stake in Astera Labs during the 2nd quarter worth about $481,000. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Astera Labs Trading Down 8.5%

Shares of ALAB opened at $206.21 on Friday. The firm has a market cap of $34.28 billion, a PE ratio of 368.23, a price-to-earnings-growth ratio of 5.62 and a beta of 1.43. The company’s 50 day simple moving average is $198.72 and its 200-day simple moving average is $124.17. Astera Labs, Inc. has a 12-month low of $47.13 and a 12-month high of $262.90.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.11. The firm had revenue of $191.93 million for the quarter, compared to analysts’ expectations of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The firm’s revenue for the quarter was up 149.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, equities research analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Michael Truett Tate sold 100,000 shares of the business’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $171.38, for a total value of $17,138,000.00. Following the transaction, the chief financial officer owned 518,996 shares in the company, valued at $88,945,534.48. The trade was a 16.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Sanjay Gajendra sold 280,000 shares of the business’s stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $170.02, for a total value of $47,605,600.00. Following the completion of the transaction, the chief operating officer owned 5,525,545 shares in the company, valued at $939,453,160.90. This trade represents a 4.82% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,308,772 shares of company stock worth $214,482,678. Insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

ALAB has been the subject of a number of recent analyst reports. Susquehanna lifted their price target on Astera Labs from $80.00 to $125.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. CICC Research initiated coverage on Astera Labs in a report on Friday, August 29th. They set an “outperform” rating and a $190.00 price target for the company. Jefferies Financial Group lifted their price target on Astera Labs from $95.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, July 22nd. Needham & Company LLC boosted their target price on Astera Labs from $100.00 to $170.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Finally, Barclays reissued an “overweight” rating and issued a $155.00 target price (up from $75.00) on shares of Astera Labs in a report on Thursday, August 7th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $159.83.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.